[Analytical validation in erythrocyte immunohematology].
In a transfusional or foeto-maternal context, hemolysis by incompatibility due to anti-erythrocyte antibodies (regular or irregular) remains the most frequent and most serious immunological risk in the receiver. In order to prevent this risk, a number of actions must be taken, such as the realization of the immunohematologic analyses for which the methodological practices have been legislated because of their serious clinical consequences. Several elements play a role in the reliability of the analyses and their results: the selection of the reagents and their validation in the routine technique used; the validation of reception; the controls involved in secondary preparations (e.g., blood cells reagent); and the daily internal controls. All this requires the choice of adapted controls and the management of possible anomalies.
Mannessier
L
L
EFS Nord-de-France, Lille, France.
Roubinet
F
F
Delamaire
M
M
Chiaroni
J
J
Lejealle
A
A
D000328:Adult; D001771:Blood Banks / Q000458:organization & administration / Q000592:standards; D001789:Blood Group Antigens / Q000032:analysis* / Q000235:genetics; D001787:Blood Group Incompatibility / Q000175:diagnosis / Q000196:embryology / Q000517:prevention & control; D001788:Blood Grouping and Crossmatching / Q000379:methods / Q000592:standards*; D003298:Coombs Test; D004910:Erythrocyte Membrane / Q000276:immunology*; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011237:Predictive Value of Tests; D011247:Pregnancy; D011785:Quality Assurance, Health Care; D011786:Quality Control; D011863:Radioimmunoassay; D015203:Reproducibility of Results; D065227:Transfusion Reaction
D001789:Blood Group Antigens